What is Zynerba Pharmaceuticals, Inc.'s current stock price?

Zynerba Pharmaceuticals, Inc. (ZYNE) currently trades at USD 1.30. Track real-time price changes and historical performance on AllInvestView.

What sector is Zynerba Pharmaceuticals, Inc. in?

Zynerba Pharmaceuticals, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Zynerba Pharmaceuticals, Inc. ZYNE Open Zynerba Pharmaceuticals, Inc. in new tab

1.30 USD

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Zynerba Pharmaceuticals, Inc. (ZYNE)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Zynerba Pharmaceuticals, Inc. Analysis (ZYNE)

United States Health Care Official Website Stock

Is Zynerba Pharmaceuticals, Inc. a good investment? Zynerba Pharmaceuticals, Inc. (ZYNE) is currently trading at 1.30 USD.

Investor FAQ

Does Zynerba Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Zynerba Pharmaceuticals, Inc.?

Zynerba Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

Company Profile

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Exchange Ticker

FRA (Germany) 6ZY.F

STU (Germany) 6ZY.SG

NGM (Sweden) ZYNE

No dividends available.

Dividends

Historical Split Corporate Actions

No corporate actions available.

Trades

Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Zynerba Pharmaceuticals, Inc. ZYNE Open Zynerba Pharmaceuticals, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Zynerba Pharmaceuticals, Inc. Analysis (ZYNE)

Investor FAQ

Company Profile

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

Zynerba Pharmaceuticals, Inc. ZYNE Open Zynerba Pharmaceuticals, Inc. in new tab

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Zynerba Pharmaceuticals, Inc. Analysis (ZYNE)

Investor FAQ

Company Profile

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

Notifications